3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
3
Peripheral Nervous System Diseases
2
Urinary Bladder Neoplasms
1
Signs and Symptoms
1
Sepsis
1
Sarcoma
1
Prostatic Neoplasms
1
Polycystic Ovary Syndrome
1
Neoplasms
1
Menstruation Disturbances
1
Febrile Neutropenia
1
Cross Infection
1
Colorectal Neoplasms
1
Interventions
Gemcitabine
29
pembrolizumab
20
Cisplatin
20
Magnetic Resonance Spectroscopy
17
Specimen Handling
16
Mitomycin
10
enfortumab vedotin
9
durvalumab
9
Cystoscopy
9
avelumab
8
Nivolumab
8
Fluorouracil
8
Carboplatin
8
Radiation
7
Cystectomy
6
atezolizumab
5
Transurethral Resection of Bladder
5
Radiotherapy
5
Mitozytrex
5
Docetaxel
5
Biopsy
5
tremelimumab
4
sacituzumab govitecan
4
erdafitinib
4
dehydroftorafur
4
Platinum
4
Immunoglobulin G
4
Disulfides
4
1,2-diaminocyclohexaneplatinum II citrate
4
disitamab vedotin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urinary Bladder Neoplasms
×
Acupuncture Therapy
×
90 days
×
Clear all
NCT07548476
2026-05-04
ACE
Dana-Farber Cancer Institute
Phase NA
Not yet recruiting
50 enrolled